Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Myriad Genetics (MYGN) Cash from Operations (2016 - 2026)

Myriad Genetics has reported Cash from Operations over the past 17 years, most recently at 10600000.0 for Q4 2025.

Quarterly Cash from Operations rose 60.61% to 10600000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1800000.0 through Dec 2025, up 120.69% year-over-year, with the annual reading at 1800000.0 for FY2025, 120.69% up from the prior year.
Cash from Operations was 10600000.0 for Q4 2025 at Myriad Genetics, down from 21100000.0 in the prior quarter.
Over five years, Cash from Operations peaked at 71800000.0 in Q1 2021 and troughed at 54700000.0 in Q4 2023.
The 5-year median for Cash from Operations is 8400000.0 (2021), against an average of 10275000.0.
Year-over-year, Cash from Operations tumbled 1029.55% in 2022 and then surged 2914.29% in 2025.
A 5-year view of Cash from Operations shows it stood at 9500000.0 in 2021, then increased by 23.16% to 7300000.0 in 2022, then plummeted by 649.32% to 54700000.0 in 2023, then surged by 112.07% to 6600000.0 in 2024, then soared by 60.61% to 10600000.0 in 2025.
Per Business Quant, the three most recent readings for MYGN's Cash from Operations are 10600000.0 (Q4 2025), 21100000.0 (Q3 2025), and 13600000.0 (Q2 2025).